Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$44.69M+127.50%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Joshua J. Ofman
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Employees
- 910
- Beta
- 3.25
- Country
- US
- Piotroski score
- 4 / 9 (Middling)
- Altman Z-score
- 6.01
Financials
Revenue
$44.69M+127.5%Net Income
$-110.25MEBITDA
$-166.71MFree Cash Flow
$-81.16MEPS (diluted)
$-2.56Shares Outstanding (diluted)
43.11M+38.8%Operating Expenses
$135.79MCash & Debt
$861.61MReturn of Capital
$0.00Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $147.17M | $-408.35M | $-11.11 |
| 2024 | $125.59M | $-2.03B | $-63.54 |
| 2023 | $93.11M | $-1.47B | $-47.20 |
| 2022 | $55.55M | $-5.40B | $-173.87 |
| 2021 | $14.61M | $-1.25B | $-40.18 |
| 2020 | $0.00 | $-312.16M | $-2.52 |
| 2019 | $0.00 | $-244.85M | $-1.99 |
| 2018 | $0.00 | $-275.72M | $-2.42 |
Valuation
GRALhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
43+333.33%Social Signal Score
Mentions (18)
- Newsprnewswire.com·17h ago·Neutral
…r Medical Oncology (ESMO) Congress, Across the Cancer Diagnostic Journey and Real-World Evidence SUNNYVALE, Calif., Oct. 5, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, will present additional data from both the NHS-Galleri trial and the PATHFINDER 2 study further evaluating the Galleri® multi-cancer early detection (MCED) test at the Early Detection of Cancer Conference (EDCC) in Edinburgh, the United Kingdom…
View source ↗ - News (RSS)fool·1d ago·Positive
Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years? Grail received some excellent news from the FDA this week, but there's still a long way to go before the company meets analyst projections.
View source ↗ - Newsfool.com·1d ago·Positive
Grail Stock Has Skyrocketed 171% in 6 Months. Where Will It Be in 5 Years? Adoption by insurers and FDA approval are critical for future performance. Profitability is not expected until 2032/2033, but revenue growth could be strong if adoption accelerates.
View source ↗ - News (RSS)fool·5d ago·Positive
3 Reasons to Buy Grail (GRAL) Hand Over Fist in October The cancer blood test maker could have a bright future.
View source ↗ - News (RSS)seekingalpha·7d ago·Neutral
GRAIL: AdCom's Vote Of Confidence Is Significant
View source ↗ - Newsdefenseworld.net·10d ago·Negative
Insider Selling: GRAIL (NASDAQ:GRAL) CFO Sells $382,694.00 in Stock GRAIL, Inc. (NASDAQ: GRAL - Get Free Report) CFO Aaron Freidin sold 4,100 shares of the company's stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $93.34, for a total transaction of $382,694.00. Following the transaction, the chief financial officer owned 248,983 shares in the company,
View source ↗ - Newsfool.com·11d ago·Neutral
Here's Why Grail Stock Surged 55% This Week Grail's stock surged 55% after a favorable FDA committee vote, and ultimately, FDA approval could drive insurer adoption and broader market access. Galleri's efficacy vote was close, reflecting ongoing concerns about effectiveness.
View source ↗ - Newswsj.com·12d ago·Neutral
Owning a Home Is Seen as a Financial Holy Grail. But What If It Isn't? There are many unrecognized trade-offs to home ownership that can make renting a better economic choice.
View source ↗ - Newswsj.com·12d ago·Neutral
Grail's Multi-Cancer Blood Test Gets FDA Committee Vote for Premarket Approval The FDA is expected to make its final ruling on Galleri's premarket approval in the coming months.
View source ↗ - Newsreuters.com·12d ago·Neutral
FDA advisers back safety of Grail's cancer test, narrowly endorses efficacy A panel of outside experts advising the US FDA backed the safety of Grail's blood-based cancer detection test, Galleri, on Wednesday, but was divided on the evidence supporting its effectiveness.
View source ↗ - Newsseekingalpha.com·14d ago·Positive
GRAIL: Stock Surges As Market Digests FDA Briefing Docs - I Broadly Concur (Rating Upgrade) GRAIL (GRAL) stock surges >30% as FDA briefing notes on Galleri cancer test signal optimism ahead of the AdCom meeting. Galleri's pivotal studies show high specificity (99.6%), PPV up to 77%, and reduced late-stage diagnoses, but sensitivity remains moderate. I assign GRAL a Buy rating, favoring FDA approval and further upside, yet acknowledge significant revenue, reimbursement, and competitive risks.
View source ↗ - Newsbarrons.com·14d ago·Negative
Grail Stock Soars 33% Ahead of Multi-Cancer Blood Test Review From FDA The biotech meets with the Food and Drug Administration this week for premarket approval of its landmark cancer blood test.
View source ↗ - Newsfool.com·27d ago·Negative
Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000 The transaction was valued at approximately $672,000. The shares traded represented 3% of the direct equity stake held by the CFO prior to the filing.
View source ↗ - Newsprnewswire.com·32d ago·Negative
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) SUNNYVALE, Calif., Sept. 3, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that it has granted equity awards in the form of restricted stock units ("RSUs") underlying an aggregate of 55,867 shares of GRAIL's common stock to 59 recently hired non-executive employees as an inducement material to their acceptance of employment wi…
View source ↗ - Newsprnewswire.com·35d ago·Negative
GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference MENLO PARK, Calif., Aug. 31, 2026 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Monday, Sep. 14 at 11:30 a.m.
View source ↗ - Newsmarketbeat.com·53d ago·Positive
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting GRAIL NASDAQ: GRAL Chief Financial Officer Aaron Freidin said the company's Galleri multi-cancer early detection test recorded strong first-half growth as it expanded distribution through digital health platforms, employers and physician offices.
View source ↗ - Newsseekingalpha.com·54d ago·Positive
GRAIL: Looking Beyond The NHS-Galleri Headline GRAIL faces a binary FDA approval event for Galleri, with significant stock movement expected based on the outcome. Despite disappointing NHS-Galleri trial results, I believe the true value of the test would have been apparent with a longer monitoring period. While GRAL has a solid cash position, commercialization delays could see the company having to raise a large amount of capital on unfavorable terms.
View source ↗ - Newsbenzinga.com·56d ago·Negative
FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test GRAIL Inc. (NASDAQ:GRAL) on Friday said it is preparing for a pivotal regulatory event as the U.S. Food and Drug Administration's (FDA) Molecular and Clinical Genetics Panel gears up to evaluate the healthcare company's flagship cancer diagnostic tool.
View source ↗
Earnings
Wed, Nov 11(in 5 weeks)
Consensus estimate $-2.50 per share
Typical surprise +23.1% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Aug 5$-2.56 vs $-2.66beat
- Tue, May 5$-2.29 vs $-2.76beat
- Thu, Feb 19$-2.44 vs $-3.33beat
- Wed, Nov 12$-2.46 vs $-3.36beat
- Tue, Aug 12$-3.18 vs $-3.14miss
- Tue, May 13$-3.10 vs $-4.03beat
Estimates and results for GRAL via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by GRAL officers and directors.
- Bought
- —
- Sold
- $143.3m
0 trades
65 trades
- Freidin Aaronsold
- Freidin Aaronsold
- Freidin Aaronsold
- Ofman Joshua J.sold
- Ofman Joshua J.sold
- Ofman Joshua J.sold
- Ofman Joshua J.sold
- Ofman Joshua J.sold
35 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in GRAL.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.